{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:37:34Z","timestamp":1786736254920,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijc.ijc_355_18","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T03:25:55Z","timestamp":1560223555000},"page":"4","source":"Crossref","is-referenced-by-count":3,"title":["Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma"],"prefix":"10.4103","volume":"56","author":[{"given":"ZekiG","family":"Surmeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ozveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Degirmenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcak","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchan","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.255482-1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0019-509X.255482-2","doi-asserted-by":"crossref","unstructured":"Echarri MJ, Lopez-Martin A, Hitt R. Targeted therapy in locally advanced and recurrent\/metastatic head and neck squamous cell carcinoma (LA-R\/M HNSCC). Cancers (Basel) 2016;8. doi: 10.3390\/cancers8030027.","DOI":"10.3390\/cancers8030027"},{"key":"key-10.4103\/0019-509X.255482-3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.255482-4","unstructured":"National Comprehensive Cancer Network Clicical Guidelines in Oncology, Head and Neck Cancers, version 2.2016. Available from: https:\/\/www.nccn.org\/. [Last accessed on 2017 Feb 17]."},{"key":"key-10.4103\/0019-509X.255482-5","unstructured":"National Comprehensive Cancer Network Clicical Guidelines in Oncology, Colon Cancer, version 2.2016. Available from: https:\/\/www.nccn.org\/. [Last accessed on 2017 Feb 17]."},{"key":"key-10.4103\/0019-509X.255482-6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/annonc\/mdp549","article-title":"Cetuximab administered once every second week to patients with metastatic colorectal cancer: A two-part pharmacokinetic\/pharmacodynamic phase I dose-escalation study","author":"Tabernero","year":"2010","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.255482-7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/annonc\/mdt116","article-title":"FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: A randomized phase II CECOG study","author":"Brodowicz","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.255482-8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12885-015-1685-z","article-title":"Multicenter phase II study of FOLFOX or biweekly XELOX and erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS\/BRAF metastatic colorectal cancer: The FLEET study","author":"Soda","year":"2015","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0019-509X.255482-9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1186\/1471-2407-14-865","article-title":"Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)","author":"Fernandez-Plana","year":"2014","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0019-509X.255482-10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6604530","article-title":"Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial","author":"Martin-Martorell","year":"2008","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.255482-11","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.6004\/jnccn.2012.0144","article-title":"A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg\/m2 for patients with recurrent or metastatic head and neck squamous cell cancer","author":"Fury","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"key-10.4103\/0019-509X.255482-12","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2015.60.7465","article-title":"Randomized multicenter phase \u0131\u0131 study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: A study of the us gastric cancer consortium","author":"Shah","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.255482-13","first-page":"808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study","author":"de","year":"1997","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.255482-14","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","article-title":"Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803","author":"Bouche","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.255482-15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/annonc\/mdh182","article-title":"Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma","author":"Mitry","year":"2004","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.255482-16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdf201","article-title":"Optimization of 5-fluorouracil (5-FU)\/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma","author":"Taieb","year":"2002","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.255482-17","first-page":"925","article-title":"Recommendations guiding physicians in biomedical research involving human subjects","author":"World","year":"1997","journal-title":"JAMA"},{"key":"key-10.4103\/0019-509X.255482-18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.255482-19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/annonc\/mdu003","article-title":"Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent\/metastatic squamous cell carcinoma of the head and neck: Results of the randomized phase I\/II ADVANTAGE trial (phase II part)","author":"Vermorken","year":"2014","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.255482-20","doi-asserted-by":"crossref","first-page":"iv340","DOI":"10.1093\/annonc\/mdu340.2","article-title":"Cetux\u0131mab (C), fluorouracil (F) and cisplatin (P) alone or with docetaxel (D) for recurrent\/metastatic (RM) head and neck cancer (HNSCC).Final analysis of AIO trial # 1108 -CEFCID","author":"Knoedler","year":"2014","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.255482-21","doi-asserted-by":"crossref","first-page":"32946","DOI":"10.1038\/srep32946","article-title":"Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent\/metastatic head and neck cancer","author":"Posch","year":"2016","journal-title":"Sci Rep"},{"key":"key-10.4103\/0019-509X.255482-22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cncr.20439","article-title":"Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck","author":"Hitt","year":"2004","journal-title":"Cancer"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:39:30Z","timestamp":1786732770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_355_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"alternative-id":["255482"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_355_18","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}